Nicox Financial Performance Report for 2024
Nicox SA has announced its financial results for 2024, highlighting a remarkable year of growth and strategic advancement. The company reported a revenue of €7.9 million, an increase from €6.9 million in 2023. This growth is attributed to innovative business decisions and solid execution of their strategic priorities.
Key Financial Highlights
Among the notable achievements, Nicox generated exceptional income amounting to €13.7 million following the transfer of VYZULTA’s future revenue stream to Soleus Capital. This transaction reflects the company's strong position and foresight into future revenue generation.
As of December 31, 2024, Nicox held cash reserves of €10.5 million, ensuring the company is well capitalized and estimated to be financed into the fourth quarter of 2025. This financial stability positions Nicox favorably as it continues to focus on its flagship product, NCX 470.
Clinical Trials and Future Milestones
Looking forward, Nicox is enthusiastic about the upcoming top-line results from the second Phase 3 clinical trial, Denali, which will evaluate NCX 470 for treating open-angle glaucoma and ocular hypertension, with results expected in the third quarter of 2025.
The company is also actively engaging in discussions and outreach efforts to establish partnerships within the U.S. for NCX 470, signaling its commitment to expand its market presence.
Revenue Breakdown and Operating Expenses
The revenue for 2024 includes an upfront payment of €3.0 million received from Kowa, granting them rights to NCX 470 in Japan, and a non-cash amount of €1.5 million that was previously recognized as prepaid income. Additionally, Nicox had internal rebilling revenues totaling €0.2 million in 2024 compared to €0.3 million in the previous year.
Operating expenses for this year amounted to €18.7 million, a notable decrease from €24.2 million in 2023. This reduction indicates effective cost management as Nicox navigates the challenges of the pharmaceutical landscape.
Net Loss and Impairment Details
Despite significant progress, Nicox reported a net loss of €22.4 million for the year, slightly higher than the €20.9 million loss reported in 2023. A contributing factor was a non-cash impairment of €27.1 million linked to a receivable from its U.S. affiliate, Nicox Ophthalmics, Inc. This was a result of revised expectations regarding the commercialization of ZERVIATE.
Business Development Strategy
In pursuit of growth, Nicox is engaged in various strategic discussions to explore the sale or licensing of certain assets, as well as other potential avenues to extend its cash runway. The company remains committed to funding its development pipeline and evaluating options that align with its long-term objectives.
About Nicox
Nicox SA is a prominent international ophthalmology company dedicated to innovative solutions that enhance vision and ocular health. NCX 470, its leading product, is a novel eye drop designed to lower intraocular pressure for glaucoma patients, embodying the company's commitment to advancing eye care.
Headquartered in Sophia Antipolis, France, Nicox is publicly traded on Euronext Growth Paris under the ticker symbol (ALCOX). It is part of the CAC Healthcare index, further emphasizing its significance in the healthcare sector.
Frequently Asked Questions
What was Nicox's revenue for 2024?
Nicox reported a revenue of €7.9 million for the full year 2024.
What is NCX 470?
NCX 470 is Nicox's flagship product, a nitric oxide-donating eye drop aimed at lowering intraocular pressure in glaucoma patients.
What are the upcoming milestones for Nicox?
The upcoming milestones include the topline results from the Denali clinical trial expected in the third quarter of 2025.
How has Nicox managed its operating expenses?
Nicox successfully reduced its operating expenses to €18.7 million in 2024, down from €24.2 million in 2023, reflecting effective cost management strategies.
Where is Nicox headquartered?
Nicox is headquartered in Sophia Antipolis, France, and is listed on the Euronext Growth Paris exchange.
